CEMPRA, INC. (NASDAQ:CEMP) Files An 8-K Other Events

CEMPRA, INC. (NASDAQ:CEMP) Files An 8-K Other Events

Story continues below

Item8.01

Other Events.

On March28, 2017, we issued a press release to report that we
have withdrawn our marketing authorization application seeking
European Medicines Agency approval in Europe of oral capsule and
intravenous formulations of solithromycin for the treatment of
community-acquired pneumonia in adults, with plans to resubmit
the application with additional data in alignment with our FDA
strategy.

A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.

Item9.01. Financial Statements and Exhibits.
(d) Exhibits

Exhibit No.

Description

99.1 Press release dated March28, 2017.


About CEMPRA, INC. (NASDAQ:CEMP)

Cempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. Solithromycin has therapeutic potential and the spectrum of activity to target pathogenic bacteria. The Company also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).

CEMPRA, INC. (NASDAQ:CEMP) Recent Trading Information

CEMPRA, INC. (NASDAQ:CEMP) closed its last trading session down -0.10 at 4.25 with 1,339,209 shares trading hands.

An ad to help with our costs